New technology at RPA helping leukaemia patients

The Haematology Laboratory at Royal Prince Alfred Hospital has recently validated and implemented two new technologies for molecular haematology testing.

The introduction of GeneXpert BCR-ABL testing has improved turnaround time for diagnosing and monitoring patients with chronic myeloid leukaemia.This has resulted in faster access to targeted therapies for patients and faster detection of therapy failure if it occurs.

The unique cartridge-based technology of the GeneXpert system also has the added benefit of reducing manual handling by laboratory staff.

Digital PCR technology has also been introduced with one test already validated on this platform and found to be more accurate and more sensitive compared to the previously used technology.

For more information contact Harry Iland 
p. 02 9515 6111